Epigenetics in Breast Cancer Therapy-New Strategies and Future Nanomedicine Perspectives
Buocikova, Verona (Biomedical Research Center of the Slovak Academy of Sciences)
Rios-Mondragon, Ivan (University of Bergen)
Pilalis, Eleftherios (Biomedical Research Foundation of the Academy of Athens)
Chatziioannou, Aristotelis (Biomedical Research Foundation of the Academy of Athens)
Miklikova, Svetlana (Biomedical Research Center of the Slovak Academy of Sciences)
Mego, Michal (Comenius University and National Cancer Institute)
Pajuste, Karlis (Latvian Institute of Organic Synthesis)
Rucins, Martins (Latvian Institute of Organic Synthesis)
Yamani, Naouale El (NILU-Norwegian Institute for Air Research)
Longhin, Eleonora Marta (NILU-Norwegian Institute for Air Research)
Sobolev, Arkadij (Latvian Institute of Organic Synthesis)
Gustà, Muriel F (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Puntes, Víctor (Institut Català de Nanociència i Nanotecnologia)
Plotniece, Aiva (Latvian Institute of Organic Synthesis)
Dusinska, Maria (NILU-Norwegian Institute for Air Research)
Cimpan, Mihaela Roxana (University of Bergen)
Gabelova, Alena (Slovak Academy of Sciences)
Smolkova, Bozena (Slovak Academy of Sciences)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	Despite advances in cancer treatment, difficult-to-treat tumor subtypes remain a challenge. New multidisciplinary approaches can help overcome current obstacles posed by tumor heterogeneity, activation and enrichment of cancer stem cells, and acquired drug resistance development. Epigenome modulation, currently unsuccessful in solid tumors due to epigenetic drug instability, toxicity, and off-target effects, might be enabled by implementing nano-based delivery strategies aiming to improve breast cancer patient outcomes. Epigenetic dysregulation has been recognized as a critical factor contributing to the development of resistance against standard chemotherapy and to breast cancer progression via epithelial-to-mesenchymal transition. Although the efficacy of the first-generation epigenetic drugs (epi-drugs) in solid tumor management has been disappointing, there is an increasing body of evidence showing that epigenome modulation, in synergy with other therapeutic approaches, could play an important role in cancer treatment, reversing acquired therapy resistance. However, the epigenetic therapy of solid malignancies is not straightforward. The emergence of nanotechnologies applied to medicine has brought new opportunities to advance the targeted delivery of epi-drugs while improving their stability and solubility, and minimizing off-target effects. Furthermore, the omics technologies, as powerful molecular epidemiology screening tools, enable new diagnostic and prognostic epigenetic biomarker identification, allowing for patient stratification and tailored management. In combination with new-generation epi-drugs, nanomedicine can help to overcome low therapeutic efficacy in treatment-resistant tumors. This review provides an overview of ongoing clinical trials focusing on combination therapies employing epi-drugs for breast cancer treatment and summarizes the latest nano-based targeted delivery approaches for epi-drugs. Moreover, it highlights the current limitations and obstacles associated with applying these experimental strategies in the clinics.
Ajuts:	European Commission 857381
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Epigenetics ; Breast cancer ; Nanomedicine ; Epi-drugs ; Targeted delivery ; Drug resistance
Publicat a:	Cancers, Vol. 12 (december 2020) , ISSN 2072-6694

DOI: 10.3390/cancers12123622
PMID: 33287297

32 p, 1.4 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències > Institut Català de Nanociència i Nanotecnologia (ICN2)
Articles > Articles de recerca
Articles > Articles publicats